Energy News / Shareholders Foundation, Inc.

NASDAQ:JUNO Investor Alert: Lawsuit Filed in Effort to Halt the Takeover of Juno Therapeutics Inc

Via: ReleaseWire

Updated 12:15 PM CST, Tue, February 20,2018

A lawsuit was filed for investors in shares of Juno Therapeutics Inc (NASDAQ:JUNO) in connection with the proposed takeover and NASDAQ:JUNO stockholders should contact the Shareholders Foundation.

San Diego, CA -- (SBWIRE) -- 02/20/2018 -- The Shareholders Foundation announces that an investor, who currently holds NASDAQ:JUNO shares, filed a lawsuit in against the proposed takeover of Juno Therapeutics Inc. by Celgene Corporation for $87 per share.

Investors who purchased shares of Juno Therapeutics Inc (NASDAQ:JUNO) and currently hold any of those NASDAQ:JUNO shares have certain options and should contact the Shareholders Foundation at or call +1(858) 779 - 1554.

On January 22, 2018, Celgene Corporation (NASDAQ:CELG) and Juno Therapeutics, Inc.(NASDAQ:JUNO) announced the signing of a merger agreement in which Celgene has agreed to acquire Juno Therapeutics Inc. Under the terms of the merger agreement, Celgene will pay $87 per share in cash, or a total of approximately $9 billion, net of cash.

The plaintiff alleges that the defendants breached their fiduciary duties owed to NASDAQ:JUNO stockholders by agreeing to sell Juno Therapeutics Inc cheaply via an unfair process to Celgene. The plaintiff claims that the proposed consideration NASDAQ:JUNO shareholders will receive is grossly inadequate and undervalues Juno Therapeutics Inc. In addition, the plaintiff alleges that the process is also unfair NASDAQ:JUNO stockholders.

On February 16, 2018, NASDAQ:JUNO shares closed at $85.10 per share.

Those who are current investors in Juno Therapeutics Inc (NASDAQ:JUNO) shares have certain options and should contact the Shareholders Foundation.

Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739

For more information on this press release visit:

Media Relations Contact
Michael Daniels
Email: Click to Email Michael Daniels